Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. The year-long sensor rests under the skin, meaning it can not be knocked off, minimizing inconveniences […]
Drug-Device Combinations
Beta Bionics increases 2026 sales guidance on 57% Q1 growth
Beta Bionics (Nasdaq:BBNX) today reported first-quarter sales results that came in ahead of the forecast on Wall Street. For the full year, the company expects sales to range between $131 million and $136 million. It previously forecast between $130 million and $135 million. Shares of Beta Bionics fell 2% to $12.03 apiece after the market […]
Abbott has positive drug-eluting scaffold data
Abbott (NYSE:ABT) today shared promising 30-day results for its Esprit BTK everolimus-eluting resorbable scaffold system. Esprit features materials similar to dissolving sutures. Unlike metal stents, it’s not a permanent implant, providing support for blocked vessels only for a few months after the blockage is cleared. At that point, the vessel can remain open on its […]
Abbott wins appeal for preliminary injunction against Sinocare in CGM patent spat
The Unified Patent Court (UPC) Court of Appeal granted Abbott (NYSE:ABT) a preliminary injunction in its patent battle against Sinocare. Abbott’s preliminary injunction victory means Sinocare is banned from selling its iCan i3 continuous glucose monitor (CGM) offering in UPC territory. The UPC decision overturned a prior ruling from a local division (LD) of The […]
Dexcom opens Athenry CGM manufacturing facility
Dexcom (Nasdaq:DXCM) said today that it has officially opened its manufacturing and office development in Athenry, Ireland. The San Diego-based continuous glucose monitor (CGM) maker broke ground on the facility in January 2024. It said in 2023 that it expected to invest $325 million in Athenry. Last month, an Irish construction company said it completed work […]
The first year-long CGM implant developer isn’t done yet
Senseonics VP of Product Development Hari Sree explains the tech behind the Eversense 365 continuous glucose monitor and what’s next in the pipeline.
Senseonics became the first company to bring a year-long continuous glucose monitor (CGM) to market with the launch of its Eversense 365 implantable system in 2024. The sensor system is different than existing transcutaneous sensors from Abbott and Dexcom, which use a small needle to measure glucose in the interstitial fluid under a patient’s skin […]
ViCentra makes Kaleido automated insulin pump immediately available with no waiting period
ViCentra announced today that it made its Kaleido automated insulin pump immediately available, with no waiting period to get started. Kaleido, a miniature, patch-style insulin pump, is currently available in Germany, the Netherlands and France. Once a healthcare provider has prescribed Kaleido and the prescription has been approved, users can move very quickly to receive […]
Medtronic has strong 1-year results for drug-coated balloon
Medtronic (NYSE:MDT) today announced new real-world data from a post-approval study of its In.Pact AV drug-coated balloon (DCB). The IN.PACT AV Access post-approval study demonstrated strong safety and effectiveness for the DCB in the treatment of arteriovenous fistula (AVF) stenoses in patients with end-stage kidney disease on dialysis. The study sought to expand real-world experience through […]
MiniMed flexes with next-gen insulin pump after spinning off from Medtronic
MiniMed Chief Product and Technology Officer Ali Dianaty explains how the former Medtronic Diabetes unit used patient feedback to develop its latest automated insulin delivery innovation.
Within two weeks of MiniMed’s initial public offering in March, the Medtronic spinoff received FDA clearance for its latest-generation MiniMed Flex automated insulin delivery system. The smaller, screenless pump system is a major milestone for one of the world’s largest diabetes businesses. “We have a long history with durable pumps,” MiniMed EVP, Chief Product and Technology Officer, Ali Dianaty said in […]
How Insulet taps into pop culture to spread the word on Omnipod through ‘Scrubs,’ Marvel
For those familiar with diabetes technology, the Omnipod platform from Insulet (Nasdaq:PODD) is one most will know about. Omnipod 5 — the world’s first available tubeless, wearable, automated insulin delivery system — is one of the leading pumps on the market. But, for those less familiar with the technology, Insulet has found new ways to […]
